













Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an 
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Background: The effect of chronic use of renin–angiotensin–aldosterone system (RAAS) 
inhibitors on the severity of COVID-19 infection is still unclear in patients with hypertension. 
We aimed to investigate the association between chronic use of angiotensin-converting 
enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and COVID-19 related 
outcomes in hypertensive patients.  
Methods: A single center study was conducted on 133 consecutive hypertensive subjects 
presenting to the Emergency Department with acute respiratory symptoms and/or fever 
who were diagnosed with COVID-19 infection between 9th and 31st March 2020.  
Results: All patients were grouped according to their chronic antihypertensive medications 
(ACEIs, N=40; ARBs, N=42; not on RAAS inhibitors, N=51). There was no statistical difference 
between ACEIs and ARBs groups in terms of hospital admission rate, oxygen therapy and 
need for non-invasive ventilation. Patients chronically treated with RAAS inhibitors showed 
a significantly lower rate of admission to semi-intensive/intensive care units, when 
compared to the non-RAAS population (odds ratio [OR] 0.25, CI95% 0.09-0.66 p=0.006). 
Similarly, the risk of mortality was lower in the former group, although not reaching 
statistical significance (OR 0.56, CI95% 0.17-1.83, p=0.341).  
Conclusions: Our data suggest that chronic use of RAAS inhibitors does not negatively affect 
clinical course of COVID-19 in hypertensive patients. Further studies are needed to confirm 
this finding and determine whether RAAS inhibitors may have a protective effect on COVID 
19-related morbidity and mortality. 













Coronavirus disease 19 (COVID-19) pandemic has affected more than 3 million people [1]. It 
has been hypothesized that chronic use of renin–angiotensin–aldosterone system (RAAS) 
inhibitors may worsen disease outcome in patients with hypertension [2]. Indeed, a defined 
receptor-binding domain of COVID-19 spike specifically recognizes angiotensin-converting 
enzyme 2 (ACE2)-receptor. ACE inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) 
determine upregulation of ACE2-receptors in cardiopulmonary circulation, making patients 
taking these drugs potentially more susceptible to increased severity [3]. Conversely, ACEIs 
and ARBs may act protectively by inhibiting RAAS hyperactivation and respiratory injury 
progression as a consequence of ACE2-receptors downregulation occurring after COVID-19 
infection [4]. However, these hypotheses are based on experimental animal models and in 
vitro studies, while clinical data are scant. For this reason, a number of scientific societies 
have recently taken a clear position opposing the discontinuation of ACEIs and ARBs in 
COVID-19 patients [5]. 
The aim of the current study was to investigate whether the chronic use of ACEIs and ARBs 













Study population and protocol 
This is a single-center retrospective study including all consecutive hypertensive subjects 
who presented to the emergency department (ED) with acute respiratory symptoms/fever, 
and were diagnosed with COVID-19 infection between 9th and 31st March 2020. We 
considered as hypertensives all the subjects undergoing chronic treatment with blood 
pressure lowering agents.  Diagnosis of COVID-19 was made by semi-quantitative real-time 
reverse transcription polymerase chain reaction on nasopharyngeal swab. Criteria for 
hospital admission of COVID-19 positive patients were established by local protocols and 
remained unchanged throughout the observation period. These included one or more of the 
following: a) respiratory failure, b) body temperature <35°C, c) presence of comorbidities, d) 
CURB-65 (confusion, uremia, respiratory rate, blood pressure, age ≥65 years) score >2, e) 
respiratory alkalosis, f) high levels of procalcitonin.  
Patients’ demographics and clinical characteristics were collected by medical records and 
entered into an anonymous database. Data included age, gender, body mass index (BMI), 
active smoking, duration of COVID-19 related symptoms prior to admission, as well as 
detailed medical history including previous cardiovascular events (myocardial 
infarction/stroke/decompensated heart failure), COPD, diabetes, and active cancer. Main 
clinical outcomes included hospitalization (immediate or delayed within 7 days after 
discharge from the ED), need for oxygen therapy, non-invasive ventilation, admission to 
semi-intensive/intensive care units (s-ICU/ICU, based on PaO2/FiO2 ratio <250 and need for 
invasive or non-invasive ventilation), and death. Additional analyses were performed after 











of hypertensives who were not on RAAS inhibitors. The study was approved by the local 
Research Ethic Committee. 
 
Statistical analysis 
Continuous variables were presented by mean and standard deviation, while binary 
variables by proportions. Comparisons across groups were made using ANOVA and Fisher’s 
exact tests, respectively. P-values were reported at their nominal value. The Benjamini-
Hochberg procedure was performed to take account of multiple testing with a 30% false 
discovery rate. Uni- and multi-variable logistic regressions were performed with a pre-
defined covariate set, which included age, gender, BMI, days with duration of symptoms 
prior to admission (days), previous cardiovascular events, diabetes and cancer, further to 
the use of ACEI/ARBs. All statistical analyses were performed using Stata 16 (College Station, 














Patients’ characteristics  
A total of 133 hypertensive patients referred to ED and diagnosed with COVID-19 were 
enrolled throughout the study period. Among these, 40 (30%) were chronically using ACEIs, 
42 (32%) ARBs, and 51 (38%) other blood pressure lowering medications. Among those 
treated with ACEis, 70% were taking ramipril, whereas olmesartan was used in more than 
50% of patients treated with ARBs (see supplementary table 1). The mean follow-up was 
15.8 ± 8.6 days. The general characteristics of the three groups are summarized in Table 1. 
No significant differences were observed for all demographics and clinical parameters, 
except for the history of chronic heart failure, which was more frequently observed in 
hypertensive patients not on RAAS inhibitors (31%; P=0.007).  
 
Use of RAAS inhibitors and clinical outcome 
At univariate analysis, the three groups had similar rates of hospital admission, as well as a 
comparable need for oxygen therapy and non-invasive ventilation during the hospital stay. 
The rate of admission to s-ICU/ICU was lower among patients treated with ACEI (23%) or 
ARBs (29%) as compared to hypertensive patients who were not on RAAS inhibitors (49%). 
The death rate was also similar between patients on ACEI and ARBs (20% and 17%, 
respectively), but lower than that observed in the third group (35%).  
Odds ratios (ORs) for hospitalization, admission to s-ICU/ICU, need for oxygen therapy, non-
invasive ventilation and death are shown in Table 2. Similar rates of hospital admission and 











patients chronically treated with RAAS inhibitors showed a lower risk of admission to s-
ICU/ICU (OR 0.36, confidence interval [CI] 95% 0.17-0.75; P=0.007). This finding remained 
significant even at multivariate analysis after adjusting for age, gender, BMI, days with 
symptoms prior to admission, previous cardiovascular events, diabetes and cancer (OR 0.25, 
CI95% 0.09-0.66; P=0.006). Despite a crude OR of 0.41 (CI 95%, 0.18-0.92; P=0.030) the 
difference in death rate between patients treated or not with RAAS inhibitors was not 




The present study shows that chronic assumption of ACEIs/ARBs did not worsen the clinical 
outcomes of COVID-19 infection in hypertensive patients. A significant lower risk of 
admission to s-ICU/ICU was observed in COVID-19 positive subjects chronically treated with 
ACEIs/ARBs as compared to other hypertensive patients, whereas the rates of 
hospitalization, oxygen therapy, non-invasive ventilation and death did not differ between 
the two groups.  
While highly expressed in the vascular endothelium and lung, ACE2-receptors have been 
shown to represent the cellular entry receptor of COVID-19 [6, 7]. Based on experimental 
animal models demonstrating an upregulation of ACE2-receptors associated with 
intravenous infusion of ACEIs and ARBs [8], it has been warned that these medications might 
negatively impact clinical course of COVID-19 in hypertensives [3, 9]. However, two previous 











activity in rat and human cells treated with RAAS inhibitors, respectively [10, 11]. Moreover, 
Tan et al. showed a protective role of ACEIs and ARBs in pneumonia prevention [12], 
suggesting that RAAS may even potentially benefit COVID-19 patients [13]. High quality 
randomized controlled trials are needed to further understand and resolve this conundrum.  
Although the rates of non-invasive ventilation did not differ between the two groups, the 
ACEIs/ARBs treated subjects were less frequently admitted to s-ICU/ICU compared to their 
counterpart. This difference was maintained even after adjusting for anthropometric and 
clinical factors (i.e. age, BMI, history of previous cardiovascular diseases, and diabetes). A 
trend of lower mortality was observed in patients on ACEIs/ARBs when compared to other 
hypertensives. Although not reaching statistical significance when analyzed in a fully 
adjusted model, this finding might further indicate that chronic ACEIs/ARBs administration 
does not negatively affect clinical outcomes in COVID-19 positive hypertensives.  
Similarly to our data, two recent Chinese studies [14] [15] reported a lower risk of COVID-19 
related mortality in hypertensive subjects associated with RAAS inhibitors during hospital 
stay. However, results were not stratified by type of chronic treatment (i.e. ARBs vs. ACEIs). 
In addition, very recent reports, based on data from electronic health records, suggested 
that treatment with ARBs/ACEIs does not correlate to an increased susceptibility to SARS-
COV-2 nor to the development of severe disease.[16-19] These evidences have been 
confirmed by our analysis, which focused on clinical outcome of a specific cohort of 
hypertensive patients referring to the ED for acute symptoms of COVID-19 infection. 
Specifically designed intervention studies are needed to confirm that the use of RAAS 











these beneficial effects (such as potential anti-inflammatory activities or protective 
modulatory effects on ACE2 expression). 
Our study presents some important limitations. First, the retrospective design and the 
limited sample size, which allowed us to only make an exploratory assessment of our 
working hypotheses. Second, only patients testing COVID-19 positive at the ED were 
enrolled in this study, thus not being representative of the entire infected population. 
Furthermore, the potential association with other antihypertensive drugs, the prosecution 
of antihypertensive therapy throughout the hospital stay and different COVID-19 specific 
therapeutic strategies might have been other confounding factors.  
In conclusion, our data suggest that chronic use of RAAS inhibitors does not correlate with 
an adverse clinical course in hypertensive patients. Conversely, discontinuing such a 
lifesaving therapy might be potentially harmful in line with societal recommendation [5]. 
Further large studies are needed to confirm whether the use of RAAS inhibitors may exert a 
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Age, years (mean, SD) 73.1 (11.5) 69.0 (13.4) 76.2 (11.9)
 
0.023* 
Gender, male (N,%) 28 (70) 31 (74) 27 (53) 0.088 
Body mass index (mean, SD) 27.5 (5.3) 28.0 (5.5) 26.1 (4.0) 0.180 
Length of stay, days (mean, SD) 9.1 (5.4) 8.5 (4.5) 11.0 (9.1) 0.423 
Symptom duration before admission, days 
(mean, SD) 
7.3 (4.9) 7.6 (2.7) 6.4 (4.5) 0.317 
Active smokers (N,%) 1 (3) 1 (3) 1 (2) 0.999 















Previous cardiovascular events (N,%) 16 (40) 13 (31) 27 (53) 0.099 
History of chronic heart failure (N,%) 4 (10) 4 (10) 16 (31) 0.007 
Diabetes (N,%) 12 (30) 8 (19) 14 (28) 0.507 
Active cancer (N,%) 9 (23) 5 (12) 7 (14) 0.436 
Chronic obstructive pulmonary disease 
(N,%) 
4 (10) 3 (7) 7 (14) 0.584 











Admission to ICU / sICU (N,%) 9 (23) 12 (29) 25 (49)
 
0.022* 
Oxygen therapy (N,%) 30 (75) 31 (74) 44 (86) 0.261 
Non-invasive ventilation (N,%) 13 (33) 14 (33) 21 (41) 0.652 
Death (N,%) 8 (20) 7 (17) 18 (35) 0.093 
* After Benjamini-Hochberg procedure no statistical significance was found at false discovery rate of 
30%. 
ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; RAAS:  renin–
angiotensin–aldosterone system; ED: emergency department; ICU: intensive care unit; sICU: semi-











Table 2. Comparison of main clinical outcomes between hypertensive patients taking or not 
renin-angiotensin-aldosterone system inhibitors.  
CI: Confidence Interval; ICU: intensive care unit; sICU: semi-intensive care unit; NIV: non-invasive 
ventilation; OR: Odds Ratio; Adj-OR: adjusted Odds Ratio. Multi-variable logistic regressions was 
performed with a pre-defined covariate set, which included age, gender, body mass index, days with 
symptoms prior to admission, previous cardiovascular events, diabetes and cancer. 
 
 
 Crude OR 95% CI P Adj-OR 95% CI P 
Hospital admission 0.45 0.09-2.24 0.327 0.39 0.05-2.94 0.365 
Oxygen therapy 0.46 0.18-1.18 0.107 0.51 0.15-1.78 0.292 
Admission to ICU /sICU 0.36 0.17-0.75 0.007 0.25 0.09-0.66 0.006 
NIV 0.70 0.34-1.44 0.336 0.58 0.21-1.60 0.296 
Death 0.41 0.18-0.92 0.030 0.56 0.17-1.83 0.341 
